Repeated doses of rhenium-186 nanoliposome for cancer that has spread to the brain lining
Original title: Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests giving a drug in repeated doses through a tube into the fluid spaces of the brain.
Who this trial is for. This study is for people with a solid tumor cancer that has spread to the lining around the brain and spinal cord. It tests a drug called rhenium-186 nanoliposome, given in repeated doses through a tube into the brain's fluid spaces.
Where it stands. The study is looking at how safe the drug is and how well it works. It also wants to find the highest dose people can handle. It will look at how far apart to give the doses and how many to give. The study has not reported results yet.
What this means, and what it doesn't
What it could mean: This study could one day point to another way to treat cancer that has spread to the brain lining. If you or someone you care for has this kind of cancer, you might ask your care team about it. The study team decides who can join.
What it doesn't mean: This is a test, not a proven treatment. Being in the study does not mean it will help you. It is not a cure, and no one can promise that it will work.
Source: ClinicalTrials.gov, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.